DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for essential tremor — screening already-approved drugs against its 39-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEssential tremor maps to a 39-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for essential tremor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
EH domain binding protein 1 (EHBP1) — EHBP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZSI · 1.914 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Only two medications, primidone and propranolol, have received Level A recommendations from the American Academy of Neurology for essential tremor. Up to 50% of patients are non-responders to these drugs. Many patients are not benefited adequately, and some not at all, despite numerous available treatments. The diagnosis and management of essential tremor is deceptively simple; isolated mild tremor may be difficult to classify, and additional features make diagnosis harder.
Essential tremor affects almost 1% of the population and can be very debilitating. Much remains unclear about its pathophysiology, environmental factors, and genetic causes. The diagnosis most likely encompasses several different conditions. A new tremor classification has been published, with axis 1 highlighting clinical characteristics and axis 2 dedicated to aetiology. The cerebello-thalamo-cortical network and its connections to other brain areas is emerging as pivotal to many tremor types. There has been ongoing debate around the clinical entity of essential tremor and its pathophysiological basis.
Treatment options include medications, adaptations, botulinum toxin injections, and functional neurosurgery. Increasing understanding of the pathophysiology is pushing forward trials of new treatment options, particularly surgical ones. With deeper phenotyping from the new classification, genetics of common tremor forms are ripe for discovery. New pharmacological therapeutic options are needed to complement the better understanding of the basis of tremor.
What is still missing is a clear pathophysiological model that can be targeted by drugs, adequate funding for trials that can move beyond the two approved medications, and a trial design that accounts for the likelihood that essential tremor is not a single condition but several, each possibly requiring different treatment. Patient stratification by phenotype or genotype remains an unmet need.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Practical Neurology · 2007 · 33 citations
Essential tremor, deceptively simple …
AbstractThe diagnosis and management of essential tremor appears deceptively simple. However, isolated mild tremor may be difficult to classify, and if the patients have any additional features the diagnosis is more difficult. Management can be challenging, despite the numerous treatments available, because so many patients are not benefited adequately and some not at all. However, as we gain a better understanding of the disorder, more effective therapies with fewer adverse effects are sure to follow.
AbstractINTRODUCTION OR BACKGROUND: Tremor is one of the commonest movement disorders and can be disabling. There are many causes and treatment options include medications, adaptations, botulinum toxin injections and functional neurosurgery. SOURCES OF DATA: Pubmed.gov peer-reviewed journal articles and reviews. AREAS OF AGREEMENT: A new tremor classification has been published. Axis 1 of this classification highlights the clinical characteristics of tremor and axis 2 is dedicated to aetiology. The cerebello-thalamo-cortical network and connections to other brain areas is emerging as pivotal to many types of tremor. AREAS OF CONTROVERSY: There has been ongoing debate around the clinical entity of essential tremor and its pathophysiological basis. GROWING POINTS: Increasing understanding of the pathophysiology underpinning tremor is helping to improve classification and is pushing forward trials of new treatment options, particularly surgical options. AREAS TIMELY FOR DEVELOPING RESEARCH: With deeper phenotyping from the new classification, genetics of common forms of tremor are ripe for discovery. New pharmacological therapeutic options are needed to complement the better understanding of the basis of tremor.
Tremor and Other Hyperkinetic Movements · 2012 · 5 citations · open access
Methodological Issues in Clinical Drug Development for Essential Tremor
AbstractEssential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.
Tidsskrift for Den norske legeforening · 2019 · 2 citations · open access
Essensiell tremor
AbstractEssential tremor affects almost 1 % of the population and may be very debilitating. Much is still unclear with regard to its pathophysiology, environmental factors and genetic causes. The diagnosis of essential tremor most likely encompasses several different conditions. In this article we provide an overview of essential tremor, pharmacological and neurosurgical treatment, as well as a review of the proposals for new definitions for tremor in general, and for essential tremor in particular.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
